DrugBiological
Pidilizumab clinical trials
Also written CT-011 and MDV9300.
- studies test it
- 14
- open now
- 1
- in phase 3
- 0
- first study started
- 2007
Keep track of what changes. Save the pidilizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 7
Medivation, Inc. (3) · CureTech Ltd (3) · Augusta University (2) · M.D. Anderson Cancer Center (1) · CARsgen Therapeutics Co., Ltd. (1) · Ohio State University Comprehensive Cancer Center (1) · Northwestern University (1) · Hadassah Medical Organization (1)
Often tested with
Tested in the same studies.
Rituximab (1) · Lenalidomide (1) · Cyclophosphamide (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses pidilizumab is read from its arms, and is right about nine times in ten.
Testing it · 14
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingPhase 1CARsgen Therapeutics Co., Ltd.NCT06560827Written as CT011 CAR-GPC3 T Cells Injection
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1Ohio State University Comprehensive Cancer CenterNCT02077959Written as pidilizumab
- Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate CancerTerminatedPhase 2Augusta UniversityNCT01420965Written as CT-011 (Anti-PD1 Antibody)
- Gemcitabine and CT-011 for Resected Pancreatic CancerTerminatedPhase 2Augusta UniversityNCT01313416Written as CT-011
- Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First RemissionTerminatedPhase 2Northwestern UniversityNCT02530125Written as Pidilizumab
- CT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWithdrawnPhase 1National Cancer Institute (NCI)NCT01386502Written as CT-011
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnPhase 2Medivation, Inc.NCT02653989Written as MDV9300
- Anti PD1 Antibody in Diffuse Intrinsic Pontine GliomaStatus unknownPhase 1/2Hadassah Medical OrganizationNCT01952769Written as MDV9300
- Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00904722Written as CT-011
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaCompletedPhase 2Medivation, Inc.NCT01435369Written as CT-011
- Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX AloneCompletedPhase 2Medivation, Inc.NCT00890305Written as CT-011
- CT-011 MAb in DLBCL Patients Following ASCTCompletedPhase 2CureTech LtdNCT00532259Written as CT-011
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionTerminatedPhase 1/2CureTech LtdNCT00962936Written as CT-011
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular CarcinomaTerminatedPhase 1/2CureTech LtdNCT00966251Written as CT-011
Given in every arm · 2 — pidilizumab is usual care beside what is tested
- Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell TransplantationCompletedPhase 2Beth Israel Deaconess Medical CenterNCT01067287Written as CT-011
- PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell VaccineTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT01441765Written as CT-011
Codes
What other systems call pidilizumab · ClinicalTrials.gg INT006415
- MeSH (NLM) C585832pidilizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) B932PAQ1BQPIDILIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7191298pidilizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71014PidilizumabOne source FDA
- DrugBank DB15383One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585832 | pidilizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | B932PAQ1BQ | PIDILIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7191298 | pidilizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71014 | Pidilizumab | One source FDA |
| DrugBank | DB15383 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.